From the Guidelines
Testosterone cypionate 25mg every 2 weeks is not a recommended treatment option for female sexual arousal disorder due to limited evidence and potential risks. Instead, treatments such as vaginal estrogen, vaginal androgens (e.g., DHEA), and integrative therapies like yoga and meditation may be considered, as they have shown some efficacy in improving sexual function in women with sexual dysfunction 1. The use of testosterone therapy in women is not well established, and its safety and efficacy are not fully understood, particularly in the context of female sexual arousal disorder 1. Therefore, alternative treatment options should be explored, and patients should be closely monitored for potential side effects and changes in their condition. Some key considerations for treating female sexual dysfunction include:
- Identifying and addressing underlying psychosocial problems or mental health issues
- Assessing and managing traditional risk factors for sexual dysfunction, such as cardiovascular disease and diabetes
- Considering the impact of cancer and its treatment on sexual function
- Evaluating the potential benefits and risks of various treatment options, including hormonal and non-hormonal therapies. It is essential to prioritize a multidimensional treatment plan that addresses the specific needs and concerns of each patient, and to involve specialists such as sexual health specialists or psychotherapists as needed 1.
From the Research
Testosterone Cypionate for Female Sexual Arousal Disorder
- There is no direct evidence in the provided studies to support the use of testosterone cypionate 25mg every 2 weeks for female sexual arousal disorder.
- However, study 2 mentions that testosterone has demonstrated some clinical benefit in women with sexual dysfunction disorders, although trials have significant design, dosing, or generalizability limitations.
- The studies primarily focus on flibanserin as a treatment option for hypoactive sexual desire disorder (HSDD) in premenopausal women, with some studies also discussing its potential use in postmenopausal women 3, 4, 5, 6.
- Flibanserin has been shown to increase the frequency of satisfying sexual events and sexual desire scores, while reducing FSD-related distress in premenopausal women diagnosed with HSDD 3, 5, 6.
- Other treatment options mentioned in the studies include buspirone, sildenafil, bupropion, bremelanotide, and herbal medications, as well as non-pharmaceutical interventions such as cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators 2.